Cost-utility of continuous-flow ventricular assist devices as bridge to transplant in pediatrics

Area of Science:

• Pediatric cardiology
• Medical device cost-effectiveness
• Heart failure management

Background:

• Continuous-flow ventricular assist devices (CF-VADs) offer a superior safety profile compared to pulsatile-flow VADs (PF-VADs).
• The higher initial cost of CF-VADs may be offset by potential long-term benefits, including outpatient support.
• Pediatric heart failure patients requiring VAD implantation present a unique population for cost-utility analysis.

Purpose of the Study:

• To analyze the cost-utility of CF-VADs versus PF-VADs in pediatric heart failure patients.
• To determine the conditions under which CF-VADs become a more cost-effective strategy.

Main Methods:

• A Markov-state transition model was developed to simulate the clinical course from VAD implantation to death.
• Data on costs and clinical outcomes were extracted from internal financial records and published literature.
• The model focused on pediatric patients with INTERMACS profile 1 or 2, eligible for either VAD type.

Main Results:

• CF-VADs were found to be more effective and less costly than PF-VADs under base-case conditions.
• Sensitivity analyses indicated that CF-VADs remained cost-effective unless specific adverse event rates were extremely high or support duration was very short (≤12 weeks).
• Key factors influencing cost-effectiveness included readmission rates, neurologic event rates, and CF-VAD discharge rates.

Conclusions:

• CF-VADs become the more cost-effective strategy after 12 weeks of support, contingent on sufficient outpatient care duration.
• Initiatives promoting earlier, safer discharges and reduced readmissions further enhance the cost-efficacy of CF-VADs.
• The long-term cost-effectiveness of CF-VADs in pediatric patients is supported by modeling data.